Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 5698
  • Home
  • Print this page
  • Email this page

   Table of Contents      
LETTER TO THE EDITOR
Year : 2016  |  Volume : 64  |  Issue : 7  |  Page : 547-548

Authors' reply


1 Department of Vitreoretina, Netra Mandir Eye Institute, Borivali, Mumbai, Maharashtra, India
2 Smt. Kanuri Santhamma Center for Vitreo Retinal Diseases, LV Prasad Eye Institute, Hyderabad, Telangana, India

Date of Web Publication9-Sep-2016

Correspondence Address:
Vivek Pravin Dave
Netra Mandir Eye Institute, Madona Colony Road, Borivali W, Mumbai - 400 103, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.190174

Rights and Permissions

How to cite this article:
Dave VP, Pappuru RR. Authors' reply. Indian J Ophthalmol 2016;64:547-8

How to cite this URL:
Dave VP, Pappuru RR. Authors' reply. Indian J Ophthalmol [serial online] 2016 [cited 2020 Feb 28];64:547-8. Available from: http://www.ijo.in/text.asp?2016/64/7/547/190174

Sir,

We thank the readers for their observations about our case report. [1],[2] Our explanation to the raised concerns is mentioned below.

We accept and apologize for the typographical errors pointed out. Regarding the diabetic status of the patient not being mentioned, the readers have quoted an article citing differences between the diabetic and nondiabetic nonarteritic ischemic optic neuropathic (NAION) cases. We would like to point out that the concerned paper concludes no clinical difference between the initial visual acuity presentation and the final visual outcome. [3] Rather all significant clinical differences are only demographic.

Fundus fluorescein angiography (FFA) findings have not been mentioned as the invasive test was not done. FFA in our case would not have changed our diagnosis or management approach. Although FFA does assist in diagnosing inflammatory pathologies, the absence of findings such as vitreous cellularity, vascular cuffing and sheathing, cystoid changes at the fovea, and hemorrhages and exudates clinically rules out inflammation. Given the advanced age of the patient, hypertensive systemic status and optic atrophy with similar complaints in the past in the other eye, the diagnosis of NAION was most suggestive without the need for further testing.

In the article that they quote, visual acuity improvement in patients similar to our presentation is mentioned to be 40%, and hence the readers say that improvement in visual acuity cannot be contributed to intravitreal bevacizumab with certainty and could be a natural history-related improvement. [4] We observe that statistically speaking a proportional confidence interval for 40% in the mentioned article varies from 26.17% (improvement in the worst case scenario) to 57.7% (improvement in the best case scenario). Thus, treating for the worst case scenario seems justified. Visual field on follow-up was not documented as the patient did not consent for the same. In any case, our therapy was directed toward the central subretinal fluid on optical coherence tomography, and thus toward central visual acuity and not change in visual field. The reference that the readers mention about resolution of macular edema actually describes optic disc edema and does not clearly mention about macular edema. [4] Although a randomized trial as the readers mention is ideal, considering an incidence of NAION of 82/100,000 persons, the logistics are clearly prohibitive. [5]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
  References Top

1.
Kalamkar C, Radke NV, Mukherjee A, Radk SN. An unusual presentation of non arteritic ischemic optic neuropathy with sub retinal fluid treated with intra vitreal bevacizumab. Indian J Ophthalmol 2016;64:546-7.  Back to cited text no. 1
  Medknow Journal  
2.
Dave VP, Pappuru RR. An unusual presentation of non arteritic ischemic optic neuropathy with sub retinal fluid treated with intra vitreal bevacizumab. Indian J Ophthalmol 2016;64:87-8.  Back to cited text no. 2
[PUBMED]  Medknow Journal  
3.
Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: Clinical characteristics in diabetic patients versus nondiabetic patients. Ophthalmology 2008;115:1818-25.  Back to cited text no. 3
[PUBMED]    
4.
Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy: Natural history of visual outcome. Ophthalmology 2008;115:298-305.e2.  Back to cited text no. 4
    
5.
Lee MS, Grossman D, Arnold AC, Sloan FA. Incidence of non-arteritic ischemic optic neuropathy: Increased risk among diabetic patients. Ophthalmology 2011;118:959-63.  Back to cited text no. 5
[PUBMED]    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed499    
    Printed1    
    Emailed0    
    PDF Downloaded83    
    Comments [Add]    

Recommend this journal